Beximco Pharmaceuticals Ltd.
BXP | IL
Overview
Corporate Details
- ISIN(s):
- US0885792061
- LEI:
- 213800IMBBD6TIOQGB56
- Country:
- Bangladesh
- Address:
- N/A
- Website:
- https://www.beximcopharma.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-13 17:10 |
Report Publication Announcement
Request of Extension to Publish Q1 Results
|
English | 11.2 KB | ||
| 2025-11-04 08:25 |
Regulatory Filings
Change of Name to Beximco Pharmaceuticals PLC.
|
English | 10.8 KB | ||
| 2025-10-27 16:53 |
Report Publication Announcement
Request of Extension to Publish Financial Results
|
English | 11.3 KB |
Automate Your Workflow. Get a real-time feed of all Beximco Pharmaceuticals Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Beximco Pharmaceuticals Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Beximco Pharmaceuticals Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea
341170
South Korea
341170
South Korea
456160
Sweden
GABA
Using an AI platform to develop allosteric therapies for neurodegenerative diseases.
United States of America
GANX
United States of America
GANX
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium
GLPG
Belgium
GLPG
A pure-play dermatology company with aesthetics, skincare, and therapeutic solutions.
Switzerland
GALD
Switzerland
GALD
Developing galectin-3 inhibitors for MASH cirrhosis, fibrosis, and cancer.
United States of America
GALT
United States of America
GALT
Develops novel small molecule drugs targeting cancer and severe fibrotic diseases.
United States of America
GLTO
United States of America
GLTO
Develops oral therapeutics for liver, metabolic, and inflammatory diseases like NASH.
United States of America
GLMD
United States of America
GLMD
Biotech firm offering cell/gene therapy CDMO services and developing immune cell cancer therapies.
South Korea
144510
South Korea
144510